Preview Mode Links will not work in preview mode

Clinical Summaries presented by InpharmD™


Jun 18, 2021

A global, phase-3 trial conducted to  evaluate the efficacy and safety of sacituzumab govitecan (Trodelvy) as compared with single-agent chemotherapy of the physician’s choice in patients with relapsed or refractory metastatic triple-negative breast cancer. This trial led to the FDA's accelerated approval of Trodelvy for this indication.